（编辑 任世碧） 证券日报网讯 10月15日晚间，百洋医药发布公告称，公司于2025年8月27日召开第三届董事会第三十三 次会议，并于2025年9月17日召开2025年第三次临时股东大会，审议通过了《关于变更注册资本并修订 的议案》。近日，公司完成了相关工商变更登记手续，并取得了青岛市行政审批服务局换发的《营业执 照》。 ...

证券日报网讯 10月15日晚间，百洋医药发布公告称，东兴证券作为公司2021年度首次公开发行股票并 在创业板上市项目（简称"上市项目"）和2023年度向不特定对象发行可转换公司债券项目（简称"可转 债项目"）的持续督导保荐机构，目前正在履行持续督导职责。东兴证券委派张羽中先生、周磊先生作 为公司保荐代表人，负责上述项目的持续督导工作，上述项目持续督导期限至募集资金使用完毕为止， 可转债项目持续督导期至2025年12月31日为止。因东兴证券原委派保荐代表人张羽中先生、周磊先生工 作变动，不再负责对公司的持续督导工作。为保证持续督导工作的有序进行，东兴证券现委派保荐代表 人朱海洲先生、姚维先生继续履行对公司持续督导的相关职责和义务。 （编辑 任世碧） ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-088 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 因东兴证券原委派保荐代表人张羽中先生、周磊先生工作变动，不再负责对公 司的持续督导工作。为保证持续督导工作的有序进行，东兴证券现委派保荐代表人 朱海洲先生、姚维先生（简历见附件）继续履行对公司持续督导的相关职责和义务。 青岛百洋医药股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 青岛百洋医药股份有限公司（以下简称"公司"）于近日收到保荐机构东兴证 券股份有限公司（以下简称"东兴证券"）出具的《关于更换持续督导保荐代表人 的函》。 东兴证券作为公司 2021 年度首次公开发行股票并在创业板上市项目（以下简称 "上市项目"）和 2023 年度向不特定对象发行可转换公司债券项目（以下简称"可 转债项目"）的持续督导保荐机构，目前正在履行持续督导职责。东兴证券委派张 羽中先生、周磊先生作为公司保荐代表人，负责上述项目的持续督导工作，上市 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-087 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 统一社会信用代码：91370200770281005N 类型：其他股份有限公司（上市） 住所：山东省青岛市市北区桐柏路 88 号 1 号楼 法定代表人：付钢 注册资本：伍亿贰仟伍佰陆拾壹万玖仟伍佰壹拾伍元整 青岛百洋医药股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开 第三届董事会第三十三次会议，并于 2025 年 9 月 17 日召开 2025 年第三次临时 股东大会，审议通过了《关于变更注册资本并修订<公司章程>的议案》，具体内 容详见公司于 2025 年 8 月 29 日在巨潮资讯网（www.cninfo.com.cn）披露的《青 岛百洋医药股份有限公司关于变更注册资本并修订<公司章程>及制定、修订、 废止相关管理制度的公告》。 近日 ...

Core Insights - The 67th American Society for Radiation Oncology (ASTRO) annual meeting showcased ZAP Surgical's ZAP-X, a cutting-edge robotic system for precise brain tumor radiation therapy, highlighting its technological advancements and clinical results [1][2] - A peer-reviewed study presented at the conference revealed significant differences in low-dose radiation spillover to healthy brain tissue across different platforms, with ZAP-X offering superior protection compared to traditional devices [1][2] Company Overview - ZAP-X is designed to optimize precision radiation therapy for brain tumors, utilizing a unique dual-rotating spherical structure that allows for thousands of non-coplanar beams, resulting in higher target doses and lower exposure to surrounding healthy tissue [2] - The system features sub-millimeter precision, real-time dose imaging, and ultra-low leakage, setting a new benchmark in safety and accuracy for radiation surgery [2] Market Position - ZAP-X has received market approval in 24 countries and regions, with over 70 global clients and more than 5,000 clinical treatments completed [2] - The company is focused on advancing the localization of ZAP-X manufacturing in China, with a new high-end manufacturing base in Beijing set to become the global production hub [2]

Core Insights - The 67th American Society for Radiation Oncology (ASTRO) annual meeting was held in San Francisco, attracting over 10,000 radiation oncology experts and scholars from around the world [1] - John R. Adler, founder and CEO of ZAP Surgical, presented the inception and technological philosophy behind ZAP-X, garnering significant interest from attendees [1] - Despite the long-standing application of Stereotactic Radiosurgery (SRS), nearly 80% of patients still lack access to high-quality treatment due to cost, facility, and technical issues, particularly in the treatment of benign and malignant brain tumors [1]

Market Overview - The pharmaceutical commercial sector increased by 0.17% on October 14, with Baiyang Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Stock Performance - Baiyang Pharmaceutical (301015) closed at 26.19, up 1.35% with a trading volume of 48,200 shares and a transaction value of 127 million [1] - China Pharmaceutical (600056) closed at 11.26, up 1.26% with a trading volume of 278,600 shares and a transaction value of 313 million [1] - Dazhenlin (603233) closed at 16.81, up 1.14% with a trading volume of 75,200 shares [1] - Other notable performers include Jianfa Zhixin (301584) up 1.01% and Renmin Tongtai (600829) also up 1.01% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 129 million from institutional investors, while retail investors saw a net inflow of 209 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are increasing their positions [2] Individual Stock Capital Flow - Saily Medical (603716) had a net inflow of 27.9 million from institutional investors, but a net outflow of 21.2 million from speculative funds [3] - Jianfa Zhixin (301584) saw a net inflow of 11.02 million from institutional investors, with a net outflow of 9.78 million from speculative funds [3] - Yifeng Pharmacy (603939) had a net inflow of 9.47 million from institutional investors, while retail investors experienced a net outflow of 13.37 million [3]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.93% on October 13, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Stock Performance - Notable stock performances included: - Seli Medical (603716) closed at 24.89, up 0.57% with a trading volume of 122,900 shares and a transaction value of 300 million yuan [1] - Zhongyao Holdings (000950) closed at 5.19, up 0.39% with a trading volume of 237,400 shares and a transaction value of 122 million yuan [1] - Baiyang Pharmaceutical (301015) closed at 25.84, down 2.67% with a trading volume of 49,400 shares and a transaction value of 128 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 180 million yuan from institutional investors, while retail investors experienced a net inflow of 123 million yuan [2] - The capital flow for specific stocks included: - Ruikang Pharmaceutical (002589) had a net inflow of 8.2952 million yuan from institutional investors [3] - Yifeng Pharmacy (603939) saw a net inflow of 5.2692 million yuan from institutional investors [3] - Guofang Shares (600538) had a net inflow of 3.8748 million yuan from institutional investors [3]

Core Insights - Baiyang Pharmaceutical experienced a 2.96% decline in stock price on October 9, with a trading volume of 158 million yuan [1] - The company reported a net financing outflow of 4.11 million yuan on the same day, with a total financing and securities balance of 500 million yuan [1][2] - For the first half of 2025, Baiyang Pharmaceutical achieved a revenue of 3.751 billion yuan, a year-on-year increase of 4.36%, while net profit attributable to shareholders decreased by 55.75% to 163 million yuan [2] Financing and Securities - On October 9, Baiyang Pharmaceutical had a financing buy-in of 18.42 million yuan, with a current financing balance of 499 million yuan, representing 3.49% of its market capitalization [1] - The company’s financing balance is above the 90th percentile of the past year, indicating a high level of financing activity [1] - The securities lending data shows that 800 shares were repaid and 4,400 shares were sold short on October 9, with a short selling amount of 119,500 yuan [1] Shareholder Information - As of June 30, the number of shareholders for Baiyang Pharmaceutical increased by 15% to 18,800, while the average circulating shares per person decreased by 13.05% to 27,926 shares [2] - The company has distributed a total of 1.551 billion yuan in dividends since its A-share listing, with 1.201 billion yuan distributed in the last three years [3] - Among the top ten circulating shareholders, ICBC Frontier Medical Stock A reduced its holdings by 3.4767 million shares, now holding 2.6816 million shares [3]

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-086 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 关于 2025 年第三季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、"百洋转债"（债券代码：123194）转股期限为 2023 年 10 月 20 日至 2029 年 4 月 13 日，最新有效的转股价格为 25.36 元/股。 2、2025 年第三季度，共有 1,159 张"百洋转债"完成转股（票面金额共计 11.59 万元人民币）；截至 2025 年第三季度末，合计共有 140,760 张"百洋转债" 完成转股（票面金额共计 1,407.60 万元人民币），合计转成 524,042 股"百洋医 药"股票（股票代码：301015）。 3、截至 2025 年第三季度末，青岛百洋医药股份有限公司（以下简称"公司"） 剩余可转换公司债券（以下简称"可转债"）为 8,459,240 张，剩余票面总金额 8 ...